Generalized Bullous Pemphigoid and Glycaemic Control in the Geriatric age Group: A Case Report

Amadi, Ekechi Stella *

Department of Internal Medicine, Dermatology Unit, Rivers State University, Nkpolu-Oroworokwu, Rivers State University Teaching Hospital, Harley Street, Port Harcourt, Nigeria and Dermatology in Clinical Practice, Faculty of Life Sciences and Education, University of South Wales, Pontypridd, United Kingdom.

Obioha, Solomon Uchenna

Anatomical Pathology, Faculty of Basic Clinical Sciences, Rivers State University, Rivers State University Teaching Hospital, Harley Street, Port Harcourt, Nigeria.

Gomba, Victoria Eno

Department of Internal Medicine, Endocrinology, Diabetes and Metabolism Unit, Rivers State University, Nkpolu-Oroworokwu, Rivers State University Teaching Hospital, Harley Street, Port Harcourt, Nigeria.

Amaewhule, Mary Nnenda

Department of Internal Medicine, Dermatology Unit, Rivers State University, Nkpolu-Oroworokwu, Rivers State University Teaching Hospital, Harley Street, Port Harcourt, Nigeria.

Figilo, Ibeinmo Moses

Department of Internal Medicine, Dermatology Unit, Rivers State University Teaching Hospital, Harley Street, Port Harcourt, Nigeria, Federal Medical Centre, Yenagoa, Nigeria.

Altraide, Dasetima Dandeson

Department of Internal Medicine, University of Port Harcourt, Dermatology Unit, Rivers State University Teaching Hospital, Harley Street, Port Harcourt, Nigeria.

*Author to whom correspondence should be addressed.


Abstract

Bullous pemphigoid (BP) is a rare autoimmunobullous disease which is seen more in the elderly. There are many factors that have been associated with BP including medications, vaccines, and different diseases including diabetes mellitus. Diabetes mellitus is known to enhance the production of autoantibodies by glycosylation of dermal proteins and increase skin fragility. This case report looks at the management of BP with consideration for glycaemic control; the accurate interpretation of the values in the older adult and emphasis on the need for multidisciplinary approach while also taking note of medication side effects.

Keywords: Corticosteroids, diabetes mellitus, generalized bullous pemphigoid, geriatric age, glycaemic control, rivaroxaban


How to Cite

Stella, A. E., Uchenna, O. S., Eno, G. V., Nnenda , A. M., Moses , F. I., & Dandeson , A. D. (2024). Generalized Bullous Pemphigoid and Glycaemic Control in the Geriatric age Group: A Case Report. Asian Journal of Case Reports in Medicine and Health, 7(1), 45–50. Retrieved from https://journalajcrmh.com/index.php/AJCRMH/article/view/185

Downloads

Download data is not yet available.

References

Nuttapatch J, Padcha P, Sinee W. Bullous pemphigoid and diabetes mellitus: a systematic review and meta-analysis, International journal of dermatology; 2024. Available:https://doi.org/10.1111/ijd.16970, Accessed (02-03-2024)

Geller S, Kremer N, Zeeli T, Spreacher F. Bullous pemphiigoid and diabetes mellitus, Are we missing a bigger picture?’ JAAD case reports. 2018;79(2):e27,

Persson MS, Harman KE, Thomas KS, Chalmers JR, Vinogradova Y, Langan SM, Hippisley-Cox J, Gran S. Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study. Br J Gen Pract. 2021;71(713):e904-e911.

Milanesi A, Weinreb JE. Diabetes in the Elderly. [Updated 2020 Sep 25]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc; 2000 Available:https://www.ncbi.nlm.nih.gov/books/NBK279147/, Accessed (02-03-2024)

Kilvert A, Fox C, Diagnosis and management of diabetes in older people . Pract. Diabetes. 2017; 34(6):195–199.

Huang L, Liu Y, Li H, Huang W, Geng R, Tang Z, Jiang Y. Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System. Int J Med Sci. 2021;18(9):1946-1952.

Bastuji- Garin, B. et al, French study Group for Bullous diseases Risk Factors for Bullous pemphigoid in the elderly: a prospective case control study, J Invest Dermatol. 2011;131(3): 637-643.

Khosravoni S. Handjani F. Alimohammadi R, Saki, N. Frequency of Neurological Disorders in Bullous Pemphigoid patients: A cross sectional study Available:https://www.hindawi.com/journals/isrn/2017/6053267/,Accessed (21-02- 2024)

Lai Y, Yew Y, Lambert, W. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta- analysis, J Eur Acad Dermatol Venereol.n 2016;30(12):2007-2015.

Oakley A, Bullous Pemphigoid; dermanetNZ; Available:https://www.dermnetnz.org/topics/bullous-pemphigoid/, Accessed (02-03-2024)

Raghav A, Ahmad J, Alam K. Nonenzymatic glycosylation of human serum albumin and its effect on antibodies profile in patients with diabetes mellitus. PLoS One. 2017;12(eCollection 2017):e0176970.

Otike-Odibi B, Amadi ES, Altraide DD, Abbey BO, Ugwa O. Case report of bullous pemphigoid in a 65 year old woman. International Journal of Research in Medical Sciences. 2020;8(7): 2669–2673.

Downham TF, Chapel TA. Bullous pemphigoid: therapy in patients with and without diabetes mellitus. Arch Dermatol. 1978;114:1639-1642.

Alexandre MI, Garrido PM, Filipe P. Treatment of Diabetes in Bullous Pemphigoid Patients: Where Do We Stand? Dermatol Pract Concept. 2023 ;13(1):e2023063

Yan ST, Xiao HY, Tian H, Li CL, Fang FS, Li XY, et al. The cutoffs and performance of glycated hemoglobin for diagnosing diabetes and prediabetes in a young and middle-aged population and in an elderly population. Diabetes Res Clin Pract. 2015;109(2):238-45.

Guo W, Zhou Q, Jia Y, Xu J. Increased Levels of Glycated Hemoglobin A1c and Iron Deficiency Anemia: A Review. Med Sci Monit. 2019; 25:8371-8378.

Chouchane K, Di Zenzo G, Pitocco D, Calabrese L, De Simone C. Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin. J Transl Med. 2021;19(1):520

Verheyden MJ, Bilgic A, Murrell DF. A Systematic Review of Drug-Induced Pemphigoid. Acta Derm Venereol. 2020;100(15)

Liang JC, Raman K, Chan SH, Tashakkor AY. Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation. CJC Open. 2021;3(10):1316-1319

Sari DA, Samodra G, Kusuma IY. Molecular mechanism of glucocorticoid-induced hyperglycemia. Pharmacy Reports. 1(1):1.